Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Development of anti-tumour agents - 20/03/2023 Drawing of the ER membrane with Sec61 channel to which the B-306 molecule binds. A pink arrow illustrates the calcium release into the cytosol.

    Targeting the protective shield of cancers

    Cancer cells have different mechanisms to help them escape destruction by the immune system. Solid tumours, for example, are often surrounded by a protective layer of lactate, which has a strong immunosuppressive effect. WMT AG from Heidelberg is developing small drug molecules that reduce lactate production and thus make cancer cells vulnerable to immune system attacks.

    https://www.gesundheitsindustrie-bw.de/en/article/news/targeting-protective-shield-cancers
  • Press release - 20/12/2022

    Enzyme inhibition promotes bone formation and curbs the development of bone metastases

    In our bones, specialized cells called osteoblasts are responsible for building up bone substance. A team of researchers led by scientists from the DKFZ-Hector Cancer Institute at the University Medical Center Mannheim* and the University Medical Center Hamburg Eppendorf has now identified an enzyme that controls the activity of osteoblasts.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/enzyme-inhibition-promotes-bone-formation-and-curbs-development-bone-metastases
  • Press release - 14/12/2022

    New drug for metastatic prostate cancer now also approved in Europe

    On December 13, 2022, the European Commission granted approval to a drug against metastatic prostate cancer whose active ingredient was developed under the leadership of the German Cancer Research Center (DKFZ) in collaboration with Heidelberg University Hospital and Heidelberg University. The drug can significantly improve the survival chances of patients.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/neues-medikament-gegen-metastasierten-prostatakrebs-nun-auch-europa-zugelassen
  • Press release - 02/11/2022

    The guardian of the (epi-)genome

    Toxicologists from the University of Konstanz have found that the protein p53 continuously protects our cells from tumorigenesis by coordinating important metabolic processes that stabilize their genomes.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/guardian-epi-genome
  • Viral cancer therapy - 26/10/2022 Microscopic image of plaque formation by HSV1 viruses (green fluorescing).

    Therapeutic viruses against tumours and metastases

    Viruses can overcome cell barriers and transfer information to their host cells. They know how to make their host cell’s infrastructure work for them. This makes them excellent biotechnological tools, which a research group from the Fraunhofer IGB in Stuttgart is using to its advantage. The team is developing a therapeutic virus that not only recognises and fights tumours, but also has the potential to reach metastases.

    https://www.gesundheitsindustrie-bw.de/en/article/news/therapeutic-viruses-against-tumours-and-metastases
  • Press release - 24/10/2022

    How tumors suppress the development of metastases

    Why do metastases often only appear after the original tumor has been surgically removed? Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim Medical Faculty of Heidelberg University have now published an explanation for this phenomenon. They were able to identify a messenger substance of the cancer cells that locally promotes the growth of the primary tumor.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/wie-tumoren-die-entstehung-von-metastasen-unterdruecken
  • Article - 14/09/2022 Radiodiagnostik von Prostatakrebs durch Positronen-Emissions-Tomografie

    Theranostics of prostate cancer: the combination of radionuclide diagnostics and radionuclide therapy

    Using a low-level radiopharmaceutical that binds to the prostate-specific membrane antigen (PSMA), positron emission tomography/computed tomography can be used to visualise even small prostate cancer metastases. Developed by Heidelberg researchers, the radiopharmaceutical is a modified radionuclide diagnostic agent that has been coupled with a powerful emitter and used as a therapeutic tracer to irradiate and destroy cancer cells from within.

    https://www.gesundheitsindustrie-bw.de/en/article/news/theranostics-prostate-cancer-combination-radionuclide-diagnostics-and-radionuclide-therapy
  • Press release - 29/06/2022

    RNA modifications in mitochondria promote invasive spread of cancer

    Mitochondria are the power plants of cells, and they contain their own genetic material and RNA molecules. Scientists from the German Cancer Research Center (DKFZ) have now discovered that certain modifications in mitochondrial RNA boost the invasive spread of cancer cells by supporting protein synthesis in mitochondria.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/rna-modifications-mitochondria-promote-invasive-spread-cancer
  • Press release - 25/04/2022

    Reprogrammed macrophages promote spread of breast cancer

    Metastatic breast cancer cells abuse macrophages, a type of immune cell, to promote the settlement of cancer metastases in the lungs. The reprogrammed macrophages stimulate blood vessel cells to secrete a cocktail of metastasis-promoting proteins that are part of the so-called metastatic niche.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/reprogrammed-macrophages-promote-spread-breast-cancer
  • Press release - 02/09/2021

    Blood vessels produce growth factor that promotes metastases

    On the one hand, blood vessels supply tumors with nutrients and, on the other, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a distant organ is promoted by factors whose production is induced by the primary tumor itself. Scientists have now identified a new growth factor produced by blood vessels that enables tumor cells to metastatically colonize organs.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/blood-vessels-produce-growth-factor-promotes-metastases
  • Press release - 07/12/2020

    One for all

    AI-based evaluation of medical imaging data usually requires a specially developed algorithm for each task. Scientists from the German Cancer Research Center (DKFZ) have now presented a new method for configuring self-learning algorithms for a large number of different imaging datasets – without the need for specialist knowledge or very significant computing power.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/one-all
  • New method for analysing blood samples - 26/11/2020 Bildschirmfoto_2020-10-30_um_11.46.25.png

    Personalised therapy monitoring for malignant melanomas

    Immunotherapy has greatly improved the survival chances of patients with malignant melanoma. A study has now begun at the Department of Dermatology at the University Hospital of Tübingen to develop a way to monitor the course of treatment as effectively as possible. It involves personalised monitoring using liquid biopsies in addition to conventional PET/CT examinations. This analysis procedure of blood samples could enable closer monitoring of…

    https://www.gesundheitsindustrie-bw.de/en/article/news/personalised-therapy-monitoring-malignant-melanomas
  • Press release - 26/10/2020

    How to prevent the spread of tumor cells via the lymph vessels

    What role do the lymphatic vessels play in the metastasis of cancer cells? Scientists from the German Cancer Research Center and the Mannheim Medical Faculty of the University of Heidelberg developed a method to investigate this question in mice. The aim of the work was to identify new ways to block the dangerous colonization and spread of tumor cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-prevent-spread-tumor-cells-lymph-vessels
  • Press release - 12/08/2020

    New technology provides insight into the development of immune cells

    The entire range of our blood and immune cells are derived from hematopoietic stem cells. Yet which genes influence how they develop into the different cell types? Scientists from the German Cancer Research Center (DKFZ) have now developed a new technology to answer this question.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-technology-provides-insight-development-immune-cells
  • Vision Zero in oncology - 02/09/2019 Titelcover_Vision-Zero.jpg

    Call for a comprehensive master plan for preventing and treating cancer

    While a cancer-free world may seem unrealistic given the increasing numbers of cancer cases, we need to reach a social consensus that cancer deaths are unacceptable and that everything possible must be done to prevent them. Leading cancer researchers around the world are calling for more investment in prevention research and cancer screening to move towards the vision of a near cancer-free world.

    https://www.gesundheitsindustrie-bw.de/en/article/news/call-for-comprehensive-master-plan-preventing-treating-cancer
  • New edition - 24/05/2019 Magnetic resonance image of brain metastases.

    Tumour metastasis

    Cancer is usually not curable when metastases have formed in the body. Metastases are often resistant to drugs that have successfully eliminated the primary tumour. The basic features of the complex process of metastasis are now known, but many details still remain elusive. Intensive research activities are focusing on new therapeutic concepts aimed at developing effective anti-metastatic therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/tumour-metastasis
  • Article - 16/04/2019 20190218_Foto_Labor_Quelle_UniversitNatsklinikum_Heidelberg.jpg

    Tumour monitoring using liquid biopsy

    Liquid biopsy, the analysis of cancer biomarkers and circulating tumour cells in body fluids such as blood, is revolutionising the diagnosis and monitoring of cancer. It has also been possible to expand circulating tumour cells from the blood under laboratory conditions. It is expected that in the future, liquid biopsy will be able to precisely characterise tumour cells at every stage of a cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/news/tumour-monitoring-using-liquid-biopsy
  • Article - 22/03/2019 Prof. Lichter (left) and Prof. Schneeweiss, who run the Translational Breast Cancer Programme in Heidelberg, in the laboratory

    Personalised therapies for treating metastasing breast cancer

    Breast cancer is characterised by broad genetic diversity. Successful treatment is made even more difficult by the fact that, in advanced breast cancer, the properties of metastases often differ significantly from the primary tumour. The Heidelberg CATCH study is now collecting genetic profiles from patients' metastasis tissue samples, which can be used to tailor therapy to individual requirements.

    https://www.gesundheitsindustrie-bw.de/en/article/news/personalisierte-therapieansaetze-bei-metastasiertem-brustkrebs
  • Article - 18/01/2018 Teaser-Mutationen-Primartumor.png

    Medications that target metastasing tumours

    Tumour metastases are often resistant to the drug that is used to eliminate the primary tumour. Genome-wide analyses of mutation patterns in the primary tumour and its metastases provide information on the aggressiveness of cancer and may help to find the best available means of further treatment. This has been demonstrated by scientists from Heidelberg in a clinical trial on the molecular evolution of renal cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/news/medications-that-target-metastasing-tumours
  • Article - 11/12/2017 The photo shows a man with glasses holding a blue cord with flags and marks in his hands.

    KDM4 – an efficient target for the therapy of triple-negative breast cancer

    While breast cancer survival has clearly improved in recent years, women with triple-negative breast cancer have benefitted very little from progress in cancer medicine. Targeted therapies aimed at inhibiting epigenetic regulators might offer a potential new option for the treatment of breast cancer. Prof. Dr. Roland Schüle and Dr. Jochen Maurer have discovered an epigenetic enzyme called KDM4 and come up with a new cell model that significantly…

    https://www.gesundheitsindustrie-bw.de/en/article/news/kdm4-an-efficient-target-for-the-therapy-of-triple-negative-breast-cancer
  • Article - 31/05/2017 The tumours can be removed using peritonectomies with HIPEC.

    Peritoneal cancer – long-term survival with good quality of life

    Thanks to an innovative treatment procedure that has been in use since 2005, surgeons from Tübingen University Hospital have been able to prolong the survival of patients with peritoneal cancer and give them a higher quality of life. This is done using a technique based on complex surgery followed by immediate intraoperative local chemotherapy on the peritoneum.

    https://www.gesundheitsindustrie-bw.de/en/article/news/peritoneal-cancer-long-term-survival-with-good-quality-of-life
  • Press release - 14/12/2016

    amcure Raises €6 Million in Series B Financing and Expands Advisory Board

    Eggenstein-Leopoldshafen – 14 December 2016: amcure, a biopharmaceutical company developing first-in-class cancer therapeutics, today announced the closing of a Series B financing round amounting to a total of EUR 6 million.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/amcure-raises-6-million-in-series-b-financing-and-expands-advisory-board
  • Article - 05/09/2016 Glioblastom_MRT.jpg

    Apogenix: immuno-oncological protein drugs for the treatment of malignant diseases

    Apogenix AG, a biopharmaceutical company from Heidelberg that specialises in immuno-oncology, develops protein drugs that target central signalling pathways involved in regulating the growth, migration and apoptosis of malfunctioning cells and thus offer novel treatment options for cancer and other malignant diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/news/apogenix-immunonkologische-proteinwirkstoffe-gegen-maligne-erkrankungen
  • Article - 22/08/2016 Schematic of a modified virus.

    Ad-O-Lytics – a new biotech start-up from Ulm

    A few years ago, Florian Kreppel developed a therapeutic approach that combined genetic vaccines with molecular address labels. It worked quite well, but the resulting product did not have the anticipated immunising properties and was put on the backburner. Now Kreppel's group of researchers is nearing completion of another project. The researchers plan to use a patented virotherapeutic platform technology for cancer treatment to establish a…

    https://www.gesundheitsindustrie-bw.de/en/article/news/ad-o-lytics-a-new-biotech-start-up-from-ulm
  • Article - 11/07/2016 riesenmitochondrien.jpg

    The toxin of natural killer cells

    Natural killer cells kill tumour cells by injecting the protein HMGB1, which blocks the production of cellular energy by aerobic respiration. Researchers from Heidelberg have elucidated this previously unknown cancer defence mechanism and are now in the process of developing a new immunotherapy for treating cancer patients.

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-toxin-of-natural-killer-cells

Page 1 / 4

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • 4
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2023
Website address: https://www.gesundheitsindustrie-bw.de/en/search